^
    1year
    CRB-601, an avβ8 blocking antibody, prevents activation of TGFb and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment (AACR 2023)
    CRB-601 is a potent and selective integrin αvβ8 blocking monoclonal antibody that can overcome tumor immune exclusion and enhance the activity of immune checkpoint inhibitors. CRB-601 antitumor activity correlated to increased αvβ8 RO and downregulation of TGFβ signaling. Investigational New Drug (IND) enabling studies are in progress.
    Immune cell
    |
    IFNG (Interferon, gamma) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    CRB-601